US FDA is mulling over how it might leverage outputs from the increasingly popular Medical Device Single Audit Program in new and diverse ways, including using MDSAP audit results in lieu of the agency's pre-market approval facility inspections.
Sean Boyd, deputy director for regulatory affairs for the Office of Compliance within FDA's Center for Devices and Radiological Health, confirmed that the agency is "looking to expand application of...